These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 10810934

  • 1. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
    Burris HA.
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K, Blackwell K.
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [Abstract] [Full Text] [Related]

  • 3. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [Abstract] [Full Text] [Related]

  • 4. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT.
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [Abstract] [Full Text] [Related]

  • 5. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA, Fields S, Peacock N.
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [Abstract] [Full Text] [Related]

  • 6. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
    Fornier M, Esteva FJ, Seidman AD.
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
    [Abstract] [Full Text] [Related]

  • 7. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
    Nabholtz JM, North S, Smylie M, Mackey J, Au HJ, Au R, Morrish D, Salter E, Tonkin K.
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
    [Abstract] [Full Text] [Related]

  • 8. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [Abstract] [Full Text] [Related]

  • 9. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
    Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M.
    J Clin Oncol; 2007 Jul 01; 25(19):2678-84. PubMed ID: 17515572
    [Abstract] [Full Text] [Related]

  • 10. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J.
    Semin Oncol; 1999 Feb 01; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [Abstract] [Full Text] [Related]

  • 11. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Crinó L, Agostara B, Conte P.
    Clin Breast Cancer; 2008 Oct 01; 8(5):453-6. PubMed ID: 18952561
    [Abstract] [Full Text] [Related]

  • 12. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA.
    Semin Oncol; 1998 Dec 01; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [Abstract] [Full Text] [Related]

  • 13. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
    Slamon D, Pegram M.
    Semin Oncol; 2001 Feb 01; 28(1 Suppl 3):13-9. PubMed ID: 11301370
    [Abstract] [Full Text] [Related]

  • 14. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
    Nabholtz JM, Crown J.
    Semin Oncol; 1998 Dec 01; 25(6 Suppl 13):4-9. PubMed ID: 9865685
    [Abstract] [Full Text] [Related]

  • 15. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD, von Minckwitz G, Raab G, Blohmer JU, Dresel V, Eidtmann H, Hilfrich J, Jackisch C, Merkle E, Gademann G, Kaufmann M.
    Semin Oncol; 1999 Jun 01; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, Lopez M.
    Clin Ter; 2008 Jun 01; 159(6):449-52. PubMed ID: 19169607
    [Abstract] [Full Text] [Related]

  • 17. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D, Antoine E.
    Semin Oncol; 1997 Aug 01; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
    Burris HA.
    Semin Oncol; 2001 Feb 01; 28(1 Suppl 3):38-44. PubMed ID: 11301373
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
    Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG, Dutch Breast Cancer Trialists' Group (BOOG).
    Clin Breast Cancer; 2011 Apr 01; 11(2):103-13. PubMed ID: 21569996
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.